Antimicrobial Agents and Chemotherapy · 2006 · 71 citations · 18 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial PharmacologyAntibiotic ResistanceAntibiotic Therapy For Foot InfectionsBacterial InfectionsFoot InfectionsClostridium PerfringensClostridium Perfringens InfectionDiabetic Foot Infection Antibiotic TherapyMicrobiology Of Foot InfectionsWound Infection Microbiology
Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC(90) of < or =0.125 microg/ml against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, and Anaerococcus prevotii), compared to respective MIC(90)s for MSSA and MRSA of 0.5 and 1 microg/ml for vancomycin, 4 and 4 microg/ml for linezolid, 0.5 and 0.5 microg/ml for daptomycin, and 0.25 and >8 microg/ml for clindamycin.
18
Manual of Clinical Microbiology.
Annals of Internal Medicine · 1980 · 14.5K citations
Economic Costs of Diabetes in the U.S. in 2002
Paul Hogan, Plamen Nikolov · Diabetes Care · 2003 · 4.2K citations
Economic Costs of Diabetes in the U.S. in 2002
Timothy M. Dall, Plamen Nikolov, Paul F. Hogan · SSRN Electronic Journal · 2003 · 484 citations · Full text